|1.||Ohlsson, Bodil: 4 articles (01/2014 - 01/2007)|
|2.||Sand, Elin: 2 articles (01/2014 - 03/2013)|
|3.||Ekblad, Eva: 2 articles (01/2014 - 03/2013)|
|4.||Roth, Bodil: 2 articles (01/2014 - 01/2013)|
|5.||Hammar, Oskar: 2 articles (03/2013 - 01/2013)|
|6.||Harada, Tasuku: 2 articles (01/2010 - 03/2009)|
|7.||Gambineri, Alessandra: 2 articles (11/2007 - 06/2007)|
|8.||Patton, Laura: 2 articles (11/2007 - 06/2007)|
|9.||Pasquali, Renato: 2 articles (11/2007 - 06/2007)|
|10.||Battocchio, M: 2 articles (09/2003 - 10/2002)|
02/01/1988 - "Intranasal and subcutaneous buserelin were well accepted and equally effective in inhibiting the pituitary-ovarian function, which caused mild menopausal symptoms but an important regression of endometriosis."
01/01/2010 - "The study demonstrated that DNG is as effective as intranasal buserelin acetate in alleviating endometriosis symptoms, and causes less bone mineral density loss, resulting in the use on a commercial basis for endometriosis patients in Japan from 2008. "
03/01/1989 - "Buserelin appears to be safe, well tolerated, and effective in the management of endometriosis and associated complaints."
06/20/1986 - "The clinical findings showed Buserelin to be effective against endometriosis. "
05/01/1992 - "We performed a randomized clinical trial to evaluate the efficacy of intranasal 400 micrograms buserelin three times daily for 6 months versus expectant management in the treatment of infertile women with pelvic endometriosis stage I or II of the revised American Fertility Society classification. "
|2.||Prostatic Neoplasms (Prostate Cancer)
11/15/1985 - "Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer."
04/23/1983 - "Buserelin offers an effective treatment of metastatic prostatic cancer without the side effects and cardiovascular risks associated with oestrogen treatment."
01/01/1988 - "Efficacy of buserelin in advanced prostate cancer and comparison with historical controls."
07/01/1986 - "Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer."
01/01/1991 - "In the ten years from 1979-1988, a total of 1725 patients with advanced prostatic cancer were entered into 28 studies, in which Buserelin as a nasal spray was the main androgen deprivation therapy. "
11/01/1990 - "In contrast, buserelin treatment caused highly significant tumor remission. "
08/01/1999 - "A significant reduction of tumor size was observed in both buserelin-treated rats and Ovx rats compared with NT rats (p<0.01). "
07/15/1993 - "Total androgen blockade with buserelin and CPA seems effective in the treatment of patients with advanced cancer of the male breast, but its superiority over standard androgen suppression remains to be demonstrated."
05/01/1989 - "4 patients cessated buserelin treatment before end of the tumor therapy, and 4 other dropped out of the study. "
07/01/1985 - "Clinical trials with buserelin in patients of reproductive age undergoing treatment for cancer should be encouraged."
10/01/1989 - "Buserelin at a dose of 1800 micrograms/day is effective in the treatment of most but not all patients with precocious puberty."
06/01/1984 - "Since a similar analog was shown to be effective in the short term parenteral treatment of idiopathic precocious puberty in girls (10), we used Buserelin both intranasally and sc to treat patients of both sexes with idiopathic and secondary central precocious puberty to test its efficacy, safety, and potential for long term use. "
02/01/1990 - "Buserelin treatment was safe and well accepted, and offers the promise of improved linear growth potential in precocious puberty."
03/01/1990 - "Buserelin represents a first-line treatment of central precocious puberty. "
11/01/1986 - "We conclude that in buserelin therapy, in the dose used in this study, does not represent optimal treatment for the initial management of patients with precocious puberty. "
12/20/1990 - "Buserelin implants in prostate carcinoma are effective for 2 or 3 months, after a single dose of 6.6 or 10 mg buserelin, respectively. "
07/01/1988 - "Buserelin was considered as an effective and safe drug to treat prostatic carcinoma."
01/01/1988 - "On the basis of our long-term studies, it can be stated that buserelin therapy induces positive therapy response in more than 75% of locally advanced, inoperable, primary prostatic carcinoma. "
09/01/2006 - "We prospectively evaluated 21 men with carcinoma of the prostate who received one implant of 9.45 mg buserelin subcutaneously. "
09/01/2006 - "(1) To determine the duration of androgen deprivation after a single buserelin implant 9.45 mg in the neoadjuvant setting in combination with curative radiation therapy of carcinoma of the prostate, and (2) to evaluate the time to recovery of gonadal function, and the incidence and duration of hypogonadal symptoms. "
|1.||Gonadotropin-Releasing Hormone (GnRH)
|6.||DNA (Deoxyribonucleic Acid)